Information has been received that Bayer has terminated the agreement with systems oncology to develop ErSO as a cancer therapy. It is unknown why this has occurred. 

ErSO is currently being used in human trials for ovarian cancer due to the compounds promising pre trial testing. https://carle.org/for-providers/research/clinical-trials/642 

We need your invaluable support to ensure that Systems Oncology moves ErSO forward urgently to Human Clinical Trials for breast cancer. 

This compound could be a game changer for those with metastatic breast cancer and I thank you all for your continued support. 

Kathy and family